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Abstract
Adenosine monophosphate–activated protein kinase (AMPK), a master regulator of cellular energy homeostasis, has
emerged as a promising molecular target in the prevention of breast cancer. Clinical trials using the United States
Food and Drug Administration (FDA)–approved, AMPK-activating, antidiabetic drug metformin are promising in this
regard, but the question of why metformin is protective for some women but not others still remains. Breast cancer
associated gene 2 (BCA2/Rabring7/RNF115), a novel Really Interesting New Gene (RING) finger ubiquitin E3 ligase, is
overexpressed in >50% of breast tumors. Herein, we report that BCA2 is an endogenous inhibitor of AMPK activation
in breast cancer cells and that BCA2 inhibition increases the efficacy of metformin. BCA2 overexpression inhibited
both basal and inducible Thr172 phosphorylation/activation of AMPKα1, while BCA2-specific small interfering RNA
(siRNA) enhanced phosphorylated AMPKα1 (pAMPKα1). The AMPK-suppressive function of BCA2 requires its E3
ligase–specific RING domain, suggesting that BCA2 targets some protein controlling (de)phosphorylation of AMPKα1
for degradation. Activation of AMPK bymetformin triggered a growth inhibitory signal but also increased BCA2 protein
levels, which correlated with AKT activation and could be curbed by an AMPK inhibitor, suggesting a potential feed-
back mechanism from pAMPKα1 to pAkt to BCA2. Finally, BCA2 siRNA, or inhibition of its upstream stabilizing kinase
AKT, increased the growth inhibitory effect ofmetformin inmultiple breast cancer cell lines, supporting the conclusion
that BCA2 weakens metformin,s efficacy. Our data suggest that metformin in combination with a BCA2 inhibitor may
be a more effective breast cancer treatment strategy than metformin alone.
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Introduction
The ubiquitin-proteasome system (UPS) is the cell
,
s primary means
by which protein homeostasis is maintained; specific protein sub-
strates such as those that are misfolded, damaged, or mutated and
may otherwise be harmful to the cell are ubiquitinated and degraded
continuously [1]. Cancer can develop as a result of disruption of the
UPS, including dysregulated degradation of specific protein targets.
Characteristic of many cancer types is the stabilization of onco-
proteins and destabilization of tumor suppressors; in this way, the
balance is tipped to allow for maximal cell survival. For example,
in some cancers, such tumor suppressor proteins like p53 and p27 are
overdegraded by the UPS, whereas growth-promoting receptors like
epidermal growth factor receptor and transforming growth factor–β
receptor are underdegraded [1]. While the proteasome has been
extensively studied as an anticancer therapeutic target, from which
bortezomib and several other effective proteasome inhibitors have
emerged [2], the roles of the individual components in the ubiquitin-
mediated steps preceding degradation, which are still not well charac-
terized, may provide us with not only more insight into how this
equilibrium is disturbed but also with novel and specific molecular
drug targets.
Ubiquitin E3 ligases provide substrate specificity to the UPS and
their imbalance has been implicated in the pathogenesis of breast
cancer [3]. Therefore, this group of enzymes has much potential as
effective and specific drug targets for the treatment of breast cancer.
An example of one such approach is the well-studied E3 ligase,
Mdm2, and its interaction with p53 for which antitumor agents have
been developed [4]. Breast cancer associated gene 2 (BCA2), like
Mdm2, belongs to the Really Interesting New Gene (RING) finger
containing subset of ubiquitin E3 ligases. The RING finger is a spe-
cialized zinc finger critical for its intrinsic autoubiquitination activity,
a trademark of all E3 ligases. Upon its discovery, BCA2 was found
to be overexpressed in breast cancer [5], linked to breast cancer cell
proliferation in vitro, and correlative to clinical disease outcome, sug-
gesting its importance in cancer progression [6]. BCA2 is expressed
in both the nucleus and cytoplasm of breast cancer cells, implying
multiple functions [6]. In hormone-responsive breast tumors, nuclear
BCA2 expression appears to be under the control of estrogen, al-
though its tumor-promoting function may not be completely depen-
dent on estrogen signaling [7]. In the cytoplasm, several binding
partners of BCA2 have been reported, including ubiquitin, UBC9,
14-3-3σ, tethrin, and hHR23a [8,9]. While these studies have great
implications in the understanding of how BCA2 is regulated, its down-
stream targets, which may contribute to overall cancer cell survival,
remain to be elucidated.
Cellular energy can be quantified in units of ATP, which is required
to be at a considerably high concentration to ensure cell survival [10].
The primary function of adenosine monophosphate–activated protein
kinase (AMPK) in the cell is to respond, much like the flip of a switch,
to drops in ATP levels, sensed by a subsequent rise in AMP and direct
binding to its β regulatory subunit. The heterotrimeric enzyme then
undergoes a conformational change, followed by phosphorylation of
its α subunit at Thr172 by upstream kinases, liver kinase B1 (LKB1),
calcium/calmodulin-dependent protein kinase 2 (CaMKK), or trans-
forming growth factor–beta-activated kinase 1 (Tak1) [11,12]. The
consequence of AMPK activation is shutdown of processes that would
further consume ATP energy, like the synthesis of fatty acids and
cholesterol, and conversely the stimulation of energy-producing path-
ways like glucose uptake and fatty acid oxidation [13]. Therefore,
AMPK regulation of cellular metabolism is necessary for both cell
survival and cell growth inhibition, complicating its role as a potential
anticancer drug target. Nevertheless, in the past 10 years, AMPK has
received a lot of attention in the cancer research field, perhaps owing
to the now widely accepted AMPK-activating ability of metformin, an
FDA-approved agent and first-line treatment for type II diabetes [14].
Although metformin is currently being assessed in phase II and III
cancer-related clinical trials, the benefit of AMPK activation in vitro
and in vivo remains controversial in various cancer types, due to a need
for more detailed mechanistic studies [15,16].
In the current study, we report that BCA2 has a negative regulatory
function on the tumor-suppressing, cellular stress–sensing kinase,
AMPK. We show that on the endogenous level, BCA2 inhibits both
basal and inducible levels of AMPKα1 phosphorylation at Thr172
and therefore its activation. This inhibition was dependent on its E3
ligase–specific RING domain and was also affected by S132/S133
mutations in its predicted Akt phosphorylation site [17]. In addition,
we demonstrate that chemical activation of AMPK by metformin or
5-amino-1-β-Dffff-ribofuranosyl-imidazole-4-carboxamide (AICAR)
also increases BCA2 and pAkt protein levels, suggesting the presence
of a possible cell survival feedback mechanism. Furthermore, the tumor
cell growth inhibitory benefit of metformin was significantly improved
once BCA2 was silenced [through small interfering RNA (siRNA)]
or destabilized [through phosphatidylinositide 3 (PI3)/Akt kinase inhi-
bition], compared to treatment with metformin alone, demonstrating
that suppression of BCA2 function is necessary for enhancement of
metformin
,
s anticancer efficacy.
Materials and Methods
Cell Culture
Human breast cancer MDA MB 231, MDA MB 468, MCF7, and
Hs578t cells and the human embryonic kidney fibroblast HEK293T
cells were obtained from the American Type Culture Collection
(Manassas, VA). MDAMB 231 andMDAMB 468 cells were cultured
in Dulbecco
,
s modified Eagle
,
s medium (DMEM), and MCF7 and
Hs578t cells in RPMI 1640 (Invitrogen, Carlsbad, CA) containing
10% FBS (Hyclone from Fisher Scientific, Pittsburgh, PA), 100 μg/
ml streptomycin, and 100 units/ml penicillin (Invitrogen). HEK293T
cells were also grown in DMEM containing 10% FBS but no anti-
biotics. Cells were passaged routinely and maintained at 37°C and
5% CO2.
Reagents
Anti-BCA2 antibody was purchased from LifeSpan BioSciences, Inc
(Seattle, WA). FLAG (M2) and β-actin antibodies were obtained from
Sigma-Aldrich Corp (St Louis, MO). Antibodies to phosphorylated
AMPK (pAMPK; Thr172), acetyl-CoA carboxylase (ACC; Ser79),
and pAKT (S473) as well as to total AMPK, ACC, and AKT were
all purchased from Cell Signaling Technology (Beverly, MA). HRP-
conjugated anti-rabbit IgG and anti-mouse IgG secondary antibodies
were from Santa Cruz Biotechnology (Santa Cruz, CA). All primary
antibodies were stored at −20°C and secondary at 4°C. The AMPK
inhibitor Compound C and DMSO were purchased from Sigma-
Aldrich Corp. AMPK activators, metformin and AICAR, were
obtained from Toronto Research Chemicals Inc (North York, Ontario)
and Tocris Bioscience (Minneapolis, MN), respectively. The PI3 kinase
inhibitor LY294002 was purchased from Cell Signaling Technology.
The stocks of these chemical reagents were made up as follows:
1380 Regulation of Metformin Response by BCA2 Buac et al. Neoplasia Vol. 15, No. 12, 2013
20 mM Compound C dissolved in DMSO, 1 M metformin in sterile
H2O, 75 mM AICAR in sterile H2O, and 10 mM LY294002 in
DMSO. All drug stocks were stored at −20°C.
Expression Vectors and Constructs
The BCA2 amplicon was subcloned into the FLAG-tagged
pCMV-tag2B vector as previously described [6,17]. Mutations in
the BCA2 RING domain and predicated AKT phosphorylation site
were engineered in each wild-type (wt) construct as also previously
described [17]. The AMPKα1 catalytic subunit (PRKAA1) pCMV6-
XL5 vector construct was purchased from the TrueClone Human
Collection, OriGene Technologies Inc (Rockville, MD). Bacterial
stocks of all vector constructs were generated in our laboratory. Once
amplified and DNA isolated, plasmid Maxiprep stocks were stored
at −20°C.
Transfection
Transfection using AMPKα and BCA2 wt and mutant constructs
(created by site-directed mutagenesis [17]). Cells were plated into
100-mm dishes at 80% confluency and allowed to settle overnight.
A fresh complete medium change, void of antibiotics, was given
2 hours before transfection. For transfection experiments using MDA
MB 231 cells, 1 to 3 μg of FLAG-BCA2, wt, S132/S133 mutant (mt;
serine 132 and 133 to alanine [8,17]), or RING (cysteine 228 and
231 to alanine [8,17]) mt vector DNA was transfected using the
Lipofectamine LTX reagent according to the manufacturer
,
s protocol
(Invitrogen), with pCMV-tag2B empty vector used as a control. Fol-
lowing a 48-hour incubation period, cells were treated as indicated,
harvested, and lysed for Western blot analysis. For co-transfection
experiments, 2.5 μg of FLAG-BCA2 wt, S132/S133, or RING mt and
2.5 μg of AMPKα vector DNA were co-transfected into HEK293T cells
using the FuGENE HD transfection reagent and protocol (Promega,
Madison, WI), using pCMV-tag2B empty vector co-transfection with
AMPKα as a control. For co-transfection experiments studying the
concentration-dependent effect of BCA2 wt or mt on AMPKα, the
AMPKα DNA concentration was held constant at 1 μg, while that of
BCA2 ranged from 1 to 5 μg. After 48 hours, cells were treated as
indicated, harvested, and lysed for Western blot analysis.
Transfection using BCA2-specific siRNA. The custom-designed
siRNA duplexes were purchased from QIAGEN (Valencia, CA)
[BCA2 siRNA duplex 2: sense, r(CGUCUGAAUAGAAUUAAUU)
dTdT, antisense, r(AAUUAAUUCUAUUCAGACG)dGdG] and dis-
solved in siRNA suspension buffer to yield a stock of 20 μmol/l, stored
at −20°C. Non-silencing control siRNA was used as a negative control
and RNAiFect (QIAGEN) as the transfection reagent. Experiments
were carried out in six-well plates following the manufacturer
,
s pro-
tocol. siRNA transfection incubation period lasted 72 hours, after
which cells were treated accordingly, harvested, lysed, and analyzed
by Western blot analysis.
Western Blot Analysis
Cells were transfected, drug treated, or both, and then harvested.
Cell lysates (30-40 μg) were mixed with 3× sodium dodecyl sulfate
buffer, boiled for 5 minutes, and analyzed by sodium dodecyl sulfate–
polyacrylamide gel electrophoresis using 4% to 20% tris-glycine
gradient gels (Invitrogen), and then transferred to polyvinylidene di-
fluoride membranes (Millipore, Billerica, MA) and blocked in 5%milk
powder in Tris-buffered saline tween 20 (0.2%; TBST) for 1 hour at
room temperature. The primary antibodies were diluted in blocking
buffer (phosphorylated antibodies at 1:500 and all remaining at
1:1000) and incubated overnight at 4°C. Membranes were washed
in TBS–Tween 20 (0.2%) and incubated with species-specific sec-
ondary antibodies conjugated to HRP (1:5000) for 1 hour at room
temperature. Signals were developed using the Immobilon Western
Chemiluminescent HRP Substrate (Millipore) and the FOTO/Analyst
Luminary/FX Systems Flexible chemiluminescent and fluorescent
imagining workstation (FOTODYNE, Hartland, WI). Densitometry
analysis was done using ImageJ software, and relative intensity was
calculated as a percentage of the control.
3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium
Bromide Assay
Cells were grown under standard conditions as described above
and seeded in 96-well plates (20,000 cells per well) and allowed to
adhere for 24 hours. BCA2 siRNA (0.75 μg) or non-silencing scram-
bled control (0.75 μg) was added for a period of 72 hours after which
metformin was added in concentrations ranging from 5 to 30 mM
for 24 hours. Cell proliferation was determined by addition of
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT;
Invitrogen). The conversion of MTT to purple formazan by viable
cells was measured using a Wallac Victor3 1420 multilabel plate
counter (550 nm) and analyzed in Microsoft Excel. Growth curves
were generated as percent of the control and statistical analysis was done
as described below.
Colony Formation Assay
An agar concentration of 0.75% in DMEM, containing 10% FBS,
100 μg/ml streptomycin, and 100 units/ml penicillin, was dispensed
at 200 μl/well of a 24-well plate to create a base layer and allowed to
solidify. MDA MB 231 cells (200 μl) in 0.4% agar were added in the
next layer (1000/well) and placed at 4°C for 5 minutes to solidify.
Cells are incubated at 37°C and 5% CO2 overnight after which
the respective drugs are added in a total volume of 200 μl/well
and colonies are allowed to form over a period of 5 to 7 days. Once
the colonies formed, iodonitrotetrazolium blue (2 mg/ml) was added at
100 μl/well and incubated overnight at 37°C and 5%CO2. Colonies of
at least 30 μm in diameter were counted using the Oxford Optronix
GelCount automated mammalian cell colony counter and CHARM
algorithm software. Colony-forming ability was determined as a
percent of those in the control.
RNA Analysis by Real-Time PCR
Total RNA was extracted using the RNeasy Mini Kit (QIAGEN)
and was reverse transcribed to cDNA (Two Step DNA kit; Invitrogen).
The cDNA was amplified using primer pairs for BCA2: forward,
5′-GGGGTCACCAGACTCACACT-3′ and reverse, 3′-CAGGAAA-
AAGGGTGTGGAGA-5′. The loading control β-actin primers are
given as follows: forward, 5′-GAGCGCGGCTACAGCTT-3′ and
reverse, 5′-TCCTTAATGTCACGCACGATTT-3′.
BCA2 Promoter–Luciferase Assay
Cells were plated into 24-well plates and co-transfected with BCA2
promoter–luciferase vector (SwitchGear Genomics, Menlo Park, CA)
and Renilla vector (Promega) as previously described [7]. After
24 hours, cells were treated with 20 mM metformin or 1 mM AICAR
for 6 hours. Luciferase activity was measured using the Dual Luciferase
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Reporter Assay Kit (Promega), and promoter activity was calculated as
relative luciferase units.
Immunoprecipitation
HEK293T cells were co-transfected with AMPKα and FLAG-
tagged BCA2 (as above), and co-immunoprecipitation was performed
using 700 μg of protein, FLAG antibody, and the Pierce Classic IP Kit
(Thermo Scientific, Rockford IL) as per the manufacturer
,
s protocol.
Statistical Analysis
Western blot densitometry analysis was performed using ImageJ
analysis software (National Institutes of Health, Bethesda, MA). All
phosphorylated proteins were normalized to corresponding total protein
expression and BCA2 to β-actin. Fold change was calculated on the basis
of the vehicle control/untreated lane, and error bars are means ± SEM for
repeated experiments. Statistical analyses of the MTT and colony for-
mation assays were carried out using an unpaired parametrical t test with
Welch
,
s correction to compare the means of six observations for each
combination treatment to the single agent condition in both the colony
formation and theMTT assays, followed by one-way analysis of variance
to compare the combination treatments to single agent and then to the
control. All statistical tests were two-tailed, and P < .05 was considered
to be statistically significant. GraphPad Prism 6 Software was used.
Results
BCA2 Is an Endogenous Inhibitor of AMPKα Thr172
Phosphorylation and Therefore Activation
To study the potential relationship between BCA2- and AMPK-
involved pathways, we first assessed the basal expression of each pro-
tein in a panel of four breast cancer cell lines (Figure 1A). We observed
an inverse relationship of BCA2 to pAMPKα1 (Thr172): Those cell
lines with higher levels of BCA2, like MDA MB 468 and Hs578t,
have lower pAMPKα1 (Thr172) levels when compared to the other
two examined, namely, MCF7 and MDA MB 231, which contain
relatively lower amounts of BCA2 but higher levels of pAMPKα1
(Thr172; Figure 1A). It has previously been reported that BCA2 con-
tains a predicted AKT phosphorylation site and that AKT-mediated
phosphorylation at this site is responsible for stabilization of the
BCA2 protein [17]. We detected levels of pAkt (S473) to be correlated
positively to that of BCA2 (Figure 1A). These data provide grounds to
further investigate the inverse relationship between BCA2 and pAMPK,
allowing us to hypothesize that BCA2 may be an endogenous inhibitor
of AMPK activation in breast cancer cells.
To provide direct support for our hypothesis, we used BCA2-
specific siRNA to inhibit the expression of BCA2 in MDA MB
231 cells, followed by measurement of subsequent levels of endogenous
pAMPKα1 (Thr172). Suppression of BCA2 occurred in an siRNA
concentration-dependent manner (reaching 80% inhibition; Fig-
ure 1B); importantly, this was accompanied by a significant (11-fold)
increase in pAMPKα1. Total AMPKα1 protein levels, however,
remained relatively unchanged (Figure 1B). To further confirm that
the increase of pAMPK was also active, the phosphorylation status
of ACC, a direct downstream target of AMPK, was assessed [18].
Knockdown of BCA2 protein resulted in a concentration-dependent
increase (up to seven-fold) in levels of phosphorylated ACC (pACC;
S79), mirroring pAMPK, while levels of total ACC were unchanged
compared to the control (Figure 1B). The non-silencing scrambled
siRNA negative control had no effect on either BCA2 protein expres-
sion or AMPK signaling (Figure 1B, lane 2 vs lane 1). When this
experiment was repeated in two other breast cancer cell lines, MCF7
and MDA MB 468 (Figure 1, C and D), inhibition (68% and 42%,
respectively) of BCA2 expression by its siRNA again resulted in
increased levels of pAMPKα1 (2.5- and 1.4-fold, respectively; Figure 1,
C and D).
More evidence of BCA2 as an endogenous AMPK inhibitor is shown
in Figure 1E , where the BCA2 gene was subcloned into a pCMV-tag2B
vector construct and herein used to co-transfect HEK293T fibroblast
cells together with a pCMV6-XL5 AMPK α1 subunit containing con-
struct. HEK293T cells express low basal levels of AMPKα1 and BCA2
(Figure 1E , lane 1), making them a good model for transfection ex-
periments. Co-transfection of the AMPKα1 subunit and the pCMV
empty vector increased cellular levels of pAMPKα1 (Figure 1E , lane 2
vs lane 1), while co-transfection of AMPKα1 and BCA2 had little or
no increase in the basal level of pAMPKα1 (Figure 1E , lane 3 vs
lane 2 vs lane 1), confirming that BCA2 inhibits basal levels of
AMPKα1 activation. To determine whether BCA2 could also inhibit
induced AMPKα activation, the co-transfected cells were treated with
AMPK activator metformin or AICAR. Metformin is an indirect acti-
vator of AMPK, while AICAR is an analog of AMP and can therefore
mimic its cellular effect and directly bind its β regulatory subunit,
activating AMPK in culture [19]. A robust induction of pAMPKα1
was observed in cells co-transfected with AMPKα and pCMV empty
vector after treatment with metformin or AICAR (Figure 1E , lanes 4
and 6 vs lane 2). Importantly, this induction was almost completely
inhibited by transfected BCA2 (Figure 1E , lane 5 vs lane 4 and lane 7
vs lane 6). Again, BCA2 transfection had little inhibitory effect on total
AMPKα1 (Figure 1E ). Therefore, these transfection studies reveal
that BCA2 is an inhibitor of both basal and induced AMPK phosphor-
ylation/activation. An increase in BCA2 levels was also observed in
response to AMPK activators (Figure 1E , lanes 4 and 6 vs lane 2),
suggesting that AMPK signaling may trigger BCA2 up-regulation as
a feedback mechanism (see Figure 4).
Requirement of the BCA2 RING Domain and S132/S133
Phosphorylation Sites for Inhibition of AMPK Activation
To gain insight into the molecular basis by which BCA2 sup-
presses AMPK activation, we determined whether its RING domain
and S132/S133 phosphorylation sites, residues within its predicted
Akt-binding domain, were required. The RING domain of BCA2 is
critical for its E3 ligase function, and a cysteine mutation to alanine, at
positions 228 and 231, renders the protein “ligase dead” and therefore
ubiquitination negative [6], while AKT-mediated phosphorylation of
BCA2 has been reported to increase its stability [8,17]. The serine 132
and 133 residues mutated to alanine would therefore increase its
ubiquitination/autoubiquitination ability and subsequent degradation
by the proteasome. It should be noted that these serines were pre-
dicted to be phosphorylated by Akt but may be susceptible to phos-
phorylation by other kinases in addition to Akt, which needs to be
further characterized.
HEK293T cells were first co-transfected with the AMPKα1 subunit
and a wt or an mt variant of BCA2, followed by examination of
the effect on basal pAMPKα1 levels by Western blot analysis. Again,
an increase in basal pAMPKα1 levels was seen when AMPKα1 was
co-transfected with the pCMV empty vector control, which was in-
hibited in the presence of BCA2 wt (Figure 2A, lanes 1-3). However,
co-transfection of the BCA2 RING mt failed to inhibit an increase
in pAMPKα1 (Figure 2A, lane 4 vs lanes 3 and 2), indicating that
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the RING domain, and therefore the E3 ligase function of BCA2, is re-
quired for negative regulation of AMPK activation. The co-transfection
of BCA2 S132/S133 mt still retained a partial inhibitory effect on
pAMPKα1 levels in this experiment, compared to BCA2 wt and RING
mt transfected cells (Figure 2A, lane 5 vs lanes 1-4), suggesting that
this mt still confers enough stability (as shown by the level of FLAG)
and therefore has partial inhibitory activity, perhaps due to its RING
domain still being intact. Levels of FLAG and total AMPKα proteins
were used as transfection efficiency controls and that of β-actin as the
loading control (Figure 2A).
To further assess the requirement of the BCA2 RING domain and
predicted AKT phosphorylation site, co-transfected HEK293T cells
Figure 1. BCA2 inhibits AMPKα1 phosphorylation and activation. (A) The assessment of basal protein expression levels in the four indicated
human breast cancer cell lines. Exponentially growing cells were lysed for Western blot analysis with specific antibodies to BCA2, pAMPK
(Thr172), total AMPKα1, pAKT (S473), total AKT, and β-actin (loading control). (B) Immunoblot of MDA MB 231 cells (grown in a six-well
plate) transfected with BCA2 siRNA (x-axis, μg) for 72 hours. Scrambled, non-silencing siRNA and untreated cells were used as controls. Cell
extracts were used for Western blots with specific antibodies to those in A as well as pACC (Ser79) and total ACC. Densitometry analysis is
a representative of the mean ± SEM for three independent experiments. pAMPK was normalized to total AMPKα, pACC to total ACC,
and BCA2 to β-actin. Fold change was calculated compared to the control. (C, D) MCF7 (C) and MDA MB 468 (D) cells were transfected
with 5 μg of either BCA2 siRNA or scrambled control for assessment of the effect on pAMPK as done in B. (E) Immunoblot of HEK293T cells
co-transfected with BCA2 wt and AMPKα1 (2.5 μg each). After a 48-hour transfection, cells were either treated with metformin (20 mM)
or AICAR (1 mM) for 6 hours or left untreated. Cell extracts were used for Western blots with specific antibodies as previously stated. FLAG
was used as a measure of transfection efficiency.
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were treated with metformin (Figure 2B). While transfection of
BCA2 wt (1 and 5 μg) inhibited the induction of pAMPKα1 by
metformin (Figure 2B, lanes 2 and 5 vs lane 1), the BCA2 RING mt
failed to do so (Figure 2B, lanes 4 and 7); in fact, a large increase
in pAMPKα1 was seen in cells transfected with 5 μg of RING mt
BCA2 (lane 7 vs lanes 4 and 1), confirming that the RING domain
of BCA2 is critical for its ability to inhibit both basal and inducible
levels of pAMPKα1, suggesting that the RING mt acts as a dominant
negative inhibitor of endogenous BCA2 function. However, the
transfection of BCA2 S132/S133 mt also inhibited AMPKα1 phos-
phorylation in a dose-dependent manner (Figure 2B, lanes 3 and 6 vs
lane 1) and this inhibition was even greater than that seen by BCA2 wt
(Figure 2B; lane 3 vs lane 2 and lane 6 vs lane 5) in this experiment.
As the predicted Akt phosphorylation site residues, the results with
this site mt were not entirely expected. While they may, in part, be
explained by the intact RING domain of this construct, as seen
under basal conditions in Figure 2A, the molecular mechanism for
such a large inhibitory effect this mt produces on inducible AMPK
remains unclear and will be further investigated in the near future.
We next progressed to confirm these results in human breast can-
cer cells. MDA MB 231 cells were transfected with increasing con-
centrations (1-5 μg/well) of BCA2 wt to observe the effect on basal
pAMPKα1 levels. In Figure 2C , it can be seen that with increasing
amounts of transfected BCA2 wt, basal AMPK phosphorylation is
prevented, with some slight activation seen in the 1 μg lane (lane 3),
but subsequent decrease with 3 and 5 μg of BCA2 wt (Figure 2C ,
lanes 4 and 5 vs lane 3). The same experiment was repeated in MDA
MB 231 cells transfected with 1 and 3 μg of BCA2 wt, RING mt,
S132/S133 mt, or pCMV empty vector control, followed by treatment
of AICAR and measurement of the effect on induced pAMPKα1
(Figure 2D). The transfection of BCA2 wt had little inhibitory activity
on inducible pAMPK levels (probably due to already high basal levels
of endogenous BCA2 and AMPKα proteins; Figure 2D, lane 2 vs
lane 1), while the transfected S132/S133 mt was again able to partly
inhibit the induction of AMPK activation (Figure 2D, lanes 3 and
5 vs lane 1). Interestingly, the decrease in endogenous BCA2 protein in
the presence of transfected S132/S133 mt compared to the RING mt
was also observed (lanes 3 and 5 vs lanes 4 and 6). This may be
explained by the still robust ubiquitination ability of this mt [17]
and therefore targeted degradation of endogenous BCA2. Importantly,
the BCA2 RING mt not only fully abolished the BCA2 inhibitory
effect but also enhanced AICAR-mediated AMPK activation in a
dose-dependent manner (Figure 2D, lanes 4 and 6 vs lanes 1 and 2).
Taken together, our data demonstrate that BCA2 E3 ligase activity
is essential for its inhibitory function on both basal and inducible
AMPK activation.
Requirement of PI3/AKT Kinase Signaling for
BCA2-Mediated AMPK Inhibition
To determine the role of AKT signaling on BCA2-mediated AMPK
suppression, we used a chemical inhibitor of the PI3/AKT kinase
signaling pathway, LY294002. Treatment of MDA MB 231 cells
with LY294002 caused a dose-dependent inhibition (>90%) of
pAkt at S473 associated with decreased levels of BCA2 protein (about
60%; Figure 3A). Importantly, this was also accompanied by a
concentration-dependent increase in pAMPKα1 levels (up to four-fold;
Figure 3A, lanes 2-5 vs lane 1). Moreover, in a kinetics experiment,
3- to 6-hour inhibition of pAkt (up to 90%) in MDA MB 231 cells
occurred and was associated with BCA2 decrease (>75%) and an up to
2-fold increase in pAMPKα1 levels, which reached its highest point
(almost 4.5-fold) at 24 hours (Figure 3B, lanes 2-5 vs lane 1). How-
ever, we again noticed an increase in BCA2 levels following AMPK
activation and return of pAkt at 6 to 24 hours (Figure 3B), consis-
tent with the idea that a potential feedback pathway is present (see
Figure 4). Our data demonstrate that the dose- and time-dependent
Figure 2. The requirement of the BCA2 RING domain and AKT phosphorylation sites for inhibition of AMPK. (A) Immunoblot of HEK293T
cells (grown in 100-mm dishes) co-transfected with AMPKα1 and BCA2 wt, RING mt, or S132/S133 mt for the assessment of basal
pAMPK levels. (B) Immunoblot of HEK293T cells co-transfected with a constant amount of AMPKα1 (1 μg) and increasing amounts
of BCA2 wt or mt (1 or 5 μg) treated with metformin (20 mM) for 6 hours. (C) Immunoblot of MDA MB 231 cells transfected with 1,
3, and 5 μg of BCA2-FLAG wt to observe the effect on pAMPK. (D) MDA MB 231 breast cancer cells transfected with increasing con-
centrations of BCA2 wt and mt (1 or 3 μg) to detect changes in inducible (by AICAR) pAMPK levels. The prepared cell extracts in
each experiment were used for Western blots with the specific antibodies as indicated. All experiments were repeated three times
for consistency, with the included figure as a representative.
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inhibition of AKT activity leads to a decrease in BCA2 levels and,
subsequently, significantly increased levels of AMPK activation.
Treatment of Breast Cancer Cells with an AMPK Activator
Increases Endogenous BCA2 Protein Levels
In our previous experiments (Figures 1–3), we noted an increase in
endogenous levels of BCA2 in response to the activation of AMPK. To
test if AMPK signaling can, in turn, lead to up-regulation of the BCA2
protein, MDA MB 231 cells were treated with various concentrations
of the direct AMPK activator, AICAR, for 2, 4, or 8 hours, followed
by measurement of the effect on BCA2 by Western blot (Figure 4A).
We observed a clear dose- and time-dependent increase in BCA2 pro-
tein levels, which corresponded to the induction of AMPK activation,
as measured by specific phosphorylation of pAMPK and pACC
(Figure 4A), demonstrating that BCA2 increase is a consequence of
AMPK activation. Because AKT can phosphorylate and stabilize
BCA2 [8,17], we determined whether AICAR treatment could also
activate AKT. Indeed, levels of pAkt were increased in MDA MB
231 cells in an AICAR concentration- and time-dependent fashion,
correlating well with that of the observed BCA2 protein increase
(Figure 4A).
When MDA MB 231 cells were treated with metformin in a
kinetics experiment, a time-dependent increase in BCA2 protein
levels was again observed, in association with an induction of AMPK
activation (Figure 4B). Furthermore, kinetics experiments using MCF7
cells treated with metformin (Figure 4C) or MDAMB 468 cells treated
with AICAR (Figure 4D) also produced increased levels of BCA2 and
pAkt proteins, associated with AMPK activation. Finally, the use of
the chemical AMPK inhibitor, Compound C, not only suppressed
activation of AMPKα1 but also inhibited the metformin-induced
increase in BCA2 in MDA MB 231 cells (Figure 4E), suggesting the
involvement of AMPK activity in a potential regulatory feedback
mechanism with pAkt and BCA2 (see Figure 6).
To determine whether the metformin-mediated increase in BCA2
occurred on the transcriptional level, BCA2 mRNA levels and pro-
moter activity were assessed in both co-transfected HEK293T and
MDA MB 231 cells before and after metformin or AICAR treat-
ment. From these experiments, we were able to conclude that AMPK
activation increases levels of BCA2 protein only but not mRNA (see
Figures W1 and W2).
Inhibition of BCA2 Significantly Enhances the Tumor
Growth Inhibitory Effect of Metformin
If BCA2 is an endogenous inhibitor of AMPK phosphorylation/
activation, it is logical to assess the growth inhibitory potential of
metformin in combination with BCA2 inhibition. To do so, breast
cancer MDA MB 231 (Figure 5A), MDA MB 486 (Figure 5B), and
Hs578t (Figure 5C ) cells were pretreated with BCA2 siRNA or nega-
tive control scrambled siRNA for 72 hours, followed by treatment
with metformin at concentrations ranging from 1 to 30 mM for an
additional 24 hours. Cell growth status was then analyzed by MTT
assay. Again, BCA2 siRNA, but not control siRNA, inhibited the
growth of MDAMB 231 breast cancer cells (59.2 vs 2.5%; Figure 5A).
The combination of metformin and the control scrambled siRNA
resulted in metformin dose-dependent growth inhibition, 5.5%,
31.0%, and 41.2% for 5, 15, and 30 mM, respectively (Figure 5A,
bars 3-5). Importantly, the addition of metformin to BCA2 siRNA-
transfected cells resulted in an even more significant reduction in
Figure 3. AKT inhibition decreases endogenous BCA2 protein levels, followed by increased AMPK activation. MDA MB 231 cells were
treated with LY294002 in either a dosing study (A; 12-hour time point) or a kinetics experiment (B; 10 μM). The included figures are repre-
sentatives of experiments done in triplicates, and the included densitometry is the mean ± SEM of phosphorylated proteins (normalized to
total) and BCA2 to β-actin, compared to vehicle control (set to 1) for fold change expression. The prepared cell extracts in each experiment
were used forWestern blots with specific antibodies to pAKT (S473), BCA2, pAMPKα (Thr172), total AMPKα1, and β-actin as loading control.
LY, LY294002.
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growth, compared to metformin plus scrambled siRNA, reaching
82.8% (P < .001) at 5 mM, 86.0% (P < .001) at 15 mM, and
92.6% (P < .001) at 30 mM (Figure 5A, bars 7-9). MDA MB 468
and Hs578t cells (Figure 5, B and C ) rendered also favorable and
statistically significant results when combining BCA2 siRNA with
metformin, compared to metformin alone. BCA2 siRNA alone was
capable of inhibiting cell growth by 68.4% in MDA MB 468, fol-
lowed by up to 89.7% inhibition with the addition of metformin
(P < .001; Figure 5B). Hs578t, while not as sensitive to such treatment
(31.1% inhibition with BCA2 siRNA), also reached up to 79% growth
inhibition with the addition of metformin (P < .05; Figure 5C).
Similarly, a soft agar, anchorage-independent, colony formation
assay was performed to further confirm the efficacy of metformin plus
BCA2 inhibition using breast cancer MDA MB 231 cells, which were
treated with either metformin alone, the PI3 kinase/AKT inhibitor
LY294002 alone (which leads to BCA2 destabilization), or their
combination (Figure 5D). The results show that the metformin and
LY294002 combination is more effective than either agent alone,
reaching 57.9% and 74.3% inhibition vs 22.5% and 40.2% with
10 and 20 mM metformin alone vs 14.8% with 10 μM LY294002
alone (bars 5 and 6 vs bars 2-4, P < .001; Figure 5D). Although
Akt has been implicated in a number of cancer cell survival pathways
and is therefore not specific to BCA2, previous published works,
together with our positively correlated data herein, indicate it to be
important for BCA2 stability and this experiment furthermore suggests
that the disruption of the BCA2-mediated feedback regulatory loop
may be a new avenue for improving metformin efficacy in breast
cancer patients with aggressive breast tumors that overexpress BCA2.
Discussion
BCA2 overexpression in breast cancer cells and its growth-promoting
activity have been well established, justifying it as a potentially attrac-
tive anticancer drug target [5–7,20]. Our current study first identifies
an inverse relationship between endogenous BCA2 and pAMPKα1
(Thr172) expression levels in multiple human breast cancer cell lines
(Figure 1A). Herein, we hypothesized that BCA2 is an endogenous
Figure 4. Activation of AMPK increases BCA2 protein levels in MDA MB 231 breast cancer cells. (A) Immunoblot of MDA MB 231 cells
treated with AICAR at the indicated concentrations and time points. (B) Immunoblot of MDAMB 231 cells treated for up to 12 hours with
20 mM metformin. (C) Immunoblot of MCF7 and (D) of MDA MB 468 cells treated with 20 mM metformin for up to 24 hours. (E) MDA
MB 231 cells were pretreated with 20 μM Compound C for 12 hours (lanes 4-6) or untreated (lanes 1-3), followed by treatment with
20 mM metformin for 4 or 8 hours (lanes 2, 3 and 5, 6). The prepared cell extracts in each experiment (representative of three repeats)
were then used for Western blots with specific antibodies as indicated.
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inhibitor of AMPK activation and that BCA2 inhibition could there-
fore increase the efficacy of metformin (Figure 6). To test these hy-
potheses, we investigated if, and how, BCA2 is involved in regulating
the tumor-suppressing AMPK signaling pathway. Toward this goal,
we have identified BCA2 as an inhibitor of an upstream event con-
trolling AMPK activation (Figure 6 and see discussion below). Fur-
thermore, our data suggest the presence of a potential feedback
mechanism where AMPK activation increases BCA2 protein expres-
sion (Figure 6). Although the existence of such a phenomenon adds
to the controversy surrounding the use of the AMPK activator met-
formin for the treatment of breast cancer, it provides newfound
awareness for the limitations that this type of therapy may have.
Posttranslational regulation of AMPK is just beginning to be
understood. As the master regulator of cellular metabolism, this field
of study has large implications in our understanding of cancer devel-
opment, progression, and even occurrence and prevention, as re-
cently nicely summarized in two review articles [21,22]. Evidence for
ubiquitination of the catalytic α and regulatory β subunits of AMPK
does exist. The E3 ligase, cidea, is the only identified E3 in this regard
to be responsible for the ubiquitination of the AMPK β subunit in brown
fat tissue, resulting in decreased AMPK activity due to proteasomal
degradation [23], whereas the α subunit–specific E3 still remains to be
discovered. Upstream of AMPK is a group of kinases including, but not
limited to, LKB1, CaMKK, Tak1,MAP/microtubule affinity-regulating
kinase 1 (MARK1), and AMPK related protein kinase 5, NUAK1, re-
sponsible for phosphorylation of the α subunit at the Thr172 site, and
evidence of their individual ubiquitination, leading to decreased AMPK
activity, also exists [24,25]. We have identified BCA2 as a negative reg-
ulator of AMPK by regulating an event(s) that controls the phosphory-
lation and dephosphorylation of the Thr172 site within the α1 subunit
(Figure 1). Immunoprecipitation experiments have revealed that BCA2
does not bind the AMPK α1 subunit directly (see Figure W3), leading
us to postulate that its negative effect is a result of BCA2 E3–mediated
degradation of a target protein that is located upstream of AMPK and
is responsible for regulating the (de)phosphorylation of the α1 subunit
(Figure 6). On this account and in conjunction with our proteomics
Figure 5. Inhibition of BCA2 enhances the antiproliferative effect of metformin. (A) MTT assay using MDA MB 231 cells transfected with
BCA2 siRNA (0.75 μg per well of a 96-well plate) for 72 hours followed by treatment with 5, 15, and 30 mM metformin for 24 hours.
Scrambled, non-silencing siRNA (0.75 μg) and untreated MDA MB 231 cells were used as controls. The included figure is a represen-
tative of three repeats, and the data are means ± SEM of those and based on an average of six observations for each condition in each
experiment (two-tailed t test with Welch
,
s correction comparing the means of combination treatment to metformin alone). (B, C) MDA
MB 468 (B) and Hs578t (C) cells were used for reproducibility of those results shown in A and are as previously described for the in-
dicated concentrations of metformin. (D) Soft agar colony formation assay using MDA MB 231 cells. Metformin (M) and LY294002 (LY)
were added at concentrations shown for 6 days. Images (inserted) shown are representatives of six independent wells from the same
treatment. The bar graph is a representative of repeated experiments, and the data are means ± SEM based on an average of six wells
per condition per experiment (two-tailed t test with Welch
,
s correction comparing means of the combination treatment to metformin
alone). ***P < .001 and ** P < .05.
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core, we have recently performed titanium dioxide (TiO2) phosphopep-
tide enrichment using MDA MB 231 cells treated with BCA2-specific
siRNA or control siRNA, followed by mass spectrometry to identify po-
tential leads that would have a place in the regulatory mechanism out-
lined within this work. We have identified several potential BCA2 target
proteins that might directly regulate AMPKα phosphorylation and de-
phosphorylation. The complete analysis of these results is currently under
way. Furthermore, the data in Figure 2 suggest that the BCA2 target
protein is also a substrate of its E3 ligase activity since the RING
domain is required for its inhibitory effect. Consistent with this argu-
ment, if this were a direct effect on the α1 subunit, we would expect
the RING mt to have a similar effect to the wt, as this would be the
substrate-binding ubiquitination site. The no change in total AMPKα
observed is also supportive in this regard (Figure 2).
Phosphorylation is possibly the most common occurring post-
translational protein modification, often resulting in changes in protein
conformation and stability, and BCA2 is no different in this regard.
The fact that the transfected BCA2 S132/S133 mt also produced an
inhibitory effect on basal pAMPKα1 in HEK293T cells (Figure 2A)
points to the importance of an intact RING domain for its inhibitory
activity. Furthermore, the even greater inhibitory effect of this mt
protein seen in the presence of metformin/AICAR (Figure 2, B and
D) also suggests the need for a more detailed characterization of these
serine mutations made within the predicted Akt phosphorylation site.
It is possible that other kinases may be in competition for phosphory-
lation of BCA2 at these sites and delineating the function of each
residue under such conditions that induce AMPK activation as in
Figure 2, B and D, is beyond the scope of this work and will be deter-
mined in future work. We also observed that the level of endogenous
BCA2 in breast cancer cells transfected with S132/S133 mt after
AICAR treatment was lower than those with BCA2 wt and RING mt
(Figure 2D). This could also be due to the ubiquitination ability of
this mt [17], which would target endogenous BCA2 protein for degra-
dation. The detailed mechanisms behind this need to be investigated.
Therefore, our BCA2 mt variant analysis data draw at least one main
conclusion: An event upstream of AMPK, regulating its (de)phosphory-
lation and activation, is likely the substrate of BCA2 E3 ligase activity
(Figures 2A and 6). The importance of AKT in suppressing AMPK
activation through BCA2 was confirmed in Figure 3 where the use
of a PI3/AKT kinase inhibitor produced a correlative effect among
pAkt inhibition, BCA2 protein decrease, and AMPK activation. These
data suggest that BCA2-mediated inhibition of AMPK activation on
the basal level is AKT-dependent.
Interest in metformin for the treatment of cancer, particularly breast
cancer, sprouted as a result of the 2005 report on reduced cancer risk
in diabetic patients to daily metformin intake, compared to diabetic
populations on other therapies [26]. Since then, thousands of papers
assessing metformin
,
s anticancer properties both in vitro and in vivo
have erupted. Phase II and III clinical trials are also under way. The
use of metformin has been experimented with in a wide variety of can-
cer types, but that is not to say without much controversy. Generally
speaking, it is agreeable that metformin works through indirect activa-
tion of AMPK. The mechanisms leading up this event are unclear,
but it is believed to be due to metformin
,
s ability to inhibit the mito-
chondrial respiratory complex I, thereby disrupting the ATP/AMP
ratio and activating AMPK [27–29]. However to our knowledge, no
direct data that show this binding taking place are available. Never-
theless, sustained activation of AMPK, and therefore limited ATP pro-
duction, is expected to produce a state of energy homeostasis halting
further energy consuming processes and creating an unfavorable en-
vironment for neoplastic cells. While many laboratories report these
results, which have been recently reviewed [30], several other groups
have also shown that AMPK activation in certain tumor types may con-
tribute to cancer cell survival through different mechanisms [31–36], of
which the downstream survival effectors have not yet been defined.
Our data show that the use of metformin and AICAR not only
activates AMPK signaling but also produces a subsequent increase in
BCA2 protein levels (Figure 4). This increase in BCA2 was further
shown to be specific to AMPK activation, as it does not occur in the
presence of the AMPK inhibitor, Compound C (Figure 4E ). Given
what is already known about BCA2 and its dependence on such a
classic growth-promoting signal as AKT, it is logical to suggest that
the observed BCA2 increase in response to AMPK activation by met-
formin or AICAR is related to a potential cell survival mechanism,
a to-be-determined feedback loop ignited by AKT, and may incite can-
cer cell growth (Figure 6). This argument was supported by increased
levels of pAKT and BCA2 proteins in AICAR- or metformin-treated
breast cancer cells (Figure 4). Directly opposing these results are
Zakikhani et al., who report inhibition of pAkt levels in response
to metformin [36]. However, it is important to note the difference in
experimental conditions between the work of Zakikhani et al. and the
current study, which may affect what results are observed. Zakikhani
et al. performed metformin treatment in serum-starved conditions for
72 hours, whereas the experiments done herein use complete media
containing 10% serum. In addition, for the purpose of our molecular
studies, AMPK activation at shorter time points is sufficient to observe
Figure 6. Proposed schematic. At the basal level, AKT works to
stabilize BCA2 so that it is free to ubiquitinate protein substrates,
including those controlling phosphorylation/dephosphorylation of
AMPKα1 at Thr172, targeting them for degradation through the
ubiquitin-proteasome pathway, resulting in inhibition of AMPK sig-
naling in breast cancer cells. The activation of AMPK by metformin
or AICAR, however, increases BCA2 protein levels, inciting a poten-
tial cancer cell survival involving PI3K/Akt. Therefore, the balance
of AMPK and PI3K/AKT/BCA2 might control breast cancer cell sen-
sitivity to metformin therapy and the tumor cell life-death switch.
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the increase in pAkt and BCA2. Furthermore, literature in support
of AMPK-activating pAkt results can be seen in various cancer types
[37–40]. The reason for these discrepancies is still unclear; however,
published reports in agreement with both observations are in existence.
To confirm the regulatory role of BCA2 on AMPK activation, we
treated three breast cancer cell lines with metformin in the absence or
presence of BCA2 inhibition. We show that through the inhibition
of BCA2, either directly by siRNA or indirectly by PI3/AKT kinase
inhibition, the desirable anticancer effect of metformin is significantly
enhanced (Figure 5).
While retrospective epidemiological data link metformin intake
to reduced overall cancer occurrence in diabetics by 30% and some
preliminary data testing its use in patients with breast cancer are
available, it is yet to be proven that metformin improves the overall
current clinical outcome for breast cancer victims, and furthermore,
in the laboratory setting, the mechanisms underlying its reported
preclinical anticancer activity are still unclear [26,41–44]. Most of
the best available therapies are beneficial to fixed tumor types, for ex-
ample, anti-estrogens for hormone-responsive breast cancers [45,46] or
Herceptin for Her2-positive cases [47]. Taking into account the mixed
reports in the literature on the effect of AMPK activation in a cancer
context, it is important to consider that metformin use may also have
beneficial or adverse effects depending on the cancer type and back-
ground, including the overexpression of BCA2. Therefore, our data
convey that the screening of breast tumors, particularly those with a
more aggressive phenotype, for BCA2 may not only provide a strong
predictor of which patients may respond to metformin-based therapies
but also suggest that the combination of metformin and a BCA2
inhibitor may be a more effective anticancer strategy than metformin
alone in which the desirable reprogrammed cellular energy homeo-
static state, characteristic of AMPK activation, could be maintained.
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Figure W3. BCA2 does not directly bind to the α subunit of AMPK.
Figure W1. The metformin-induced BCA2 protein increase is not
due to increased transcription.
Figure W2. BCA2 promoter activity is not increased in response to (A) metformin or (B) AICAR treatment.
